Abstract
Objectives: To elucidate the association between thrombospondin1 (THBS1) expression and TP53 status and THBS1 promoter methylation in epithelial ovarian cancer (EOC).Methods: Epithelial ovarian cancer cell lines with known TP53 status were analyzed for THBS1 gene expression using Affymetrix U133 microarrays and promoter methylation by pyrosequencing. THBS1 mRNA expression was obtained pre- and post-exposure to radiation and hypoxia treatment in A2780 parent wild-type (wt) and mutant (m)TP53 cells. THBS1 expression was compared to tumor growth properties.Results: THBS1 gene expression was higher in cells containing a wtTP53 gene or null TP53 mutation (p = 0.005) and low or absent p53 protein expression (p = 0.008) compared to those harboring a missense TP53 gene mutation and exhibiting high p53 protein expression. Following exposure to radiation, there was a 3.4-fold increase in THBS1 mRNA levels in the mTP53 versus wtTP53 A2780 cells. After exposure to hypoxia, THBS1 mRNA levels increased approximately fourfold in both wtTP53 and mTP53 A2780 cells. Promoter methylation levels were low (median = 8.6%; range = 3.5–88.8%). There was a non-significant inverse correlation between THBS1 methylation and transcript levels. There was no association between THBS1 expression and population doubling time, invasive capacity, or anchorage-independent growth.Conclusion: THBS1 expression may be regulated via the TP53 pathway, and induced by hypoxic tumor microenvironment conditions. Overall low levels of THBS1 promoter methylation imply that methylation is not the primary driver of THBS1 expression in EOC.
Highlights
Thrombospondin1 (THBS1) is a potent modulator of angiogenesis that has been shown to have both stimulatory [1,2,3,4,5,6] and inhibitory effects [7, 8] on the process of tumor neovascularization, proliferation, invasiveness, and progression
Results:THBS1 gene expression was higher in cells containing a wtTP53 gene or nullTP53 mutation (p = 0.005) and low or absent p53 protein expression (p = 0.008) compared to those harboring a missense TP53 gene mutation and exhibiting high p53 protein expression
Overall low levels of THBS1 promoter methylation imply that methylation is not the primary driver of THBS1 expression in epithelial ovarian cancer (EOC)
Summary
Thrombospondin (THBS1) is a potent modulator of angiogenesis that has been shown to have both stimulatory [1,2,3,4,5,6] and inhibitory effects [7, 8] on the process of tumor neovascularization, proliferation, invasiveness, and progression. We previously demonstrated that THBS1 protein expression was associated with clinical outcome in women with advanced epithelial ovarian cancer (EOC) who were treated with taxane and platinum-based chemotherapy regimens [9]. Women whose cancers had high compared to low THBS1 protein expression had worse progression-free (PFS) and overall survival (OS). Exploratory adjusted Cox regression modeling revealed that women whose cancers overexpressed p53 protein, which reflects the presence of missense TP53 mutations, and expressed high THBS1 had a threefold elevation in the risk of disease progression and death compared with women whose cancers didn’t overexpress p53 or those that overexpressed p53 and expressed low THBS1 [9]. TP53 mutations are present in over 90% of high-grade serous ovarian cancers [12] and represent a plausible mechanism of controlling epigenetic regulation of gene transcription
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
